Status:
TERMINATED
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
Lead Sponsor:
AstraZeneca
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a ...
Eligibility Criteria
Inclusion
- Patients with AML, a certain type of ALL, NHL and MM
- certain types of cancer of the lymph nodes
- certain types of leukemias (blood cancers)
- disease has or will fail with other treatments
- relatively good overall health other than your cancer
Exclusion
- poor bone marrow function (not producing enough blood cells)
- serious heart conditions
- poor liver or kidney function
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00460460
Start Date
March 1 2007
End Date
August 1 2007
Last Update
January 25 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research site
Buffalo, New York, United States
2
Research Site
New York, New York, United States
3
Research Site
Toronto, Ontario, Canada